DOCSLIB.ORG

Kanuma (Sebelipase Alfa) Original Effective Date: 11/21/2016 04/24 Policy Number: MCP-289 Revision Date(S)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kanuma (Sebelipase Alfa) Original Effective Date: 11/21/2016 04/24 Policy Number: MCP-289 Revision Date(S) Subject: Kanuma (sebelipase alfa) Original Effective Date: 11/21/2016 04/24 Policy Number: MCP-289 Revision Date(s): Review Date(s): 12/15/2016; 9/19/2017, 9/13/2018 MCPC Approval Date: 9/13/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP document and provide the directive for all Medicare members. SUMMARY OF EVIDENCE/POSITION This policy addresses the coverage of Kanuma (sebelipase alfa), a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme administered intravenously for the treatment of the rare disease lysosomal acid lipase deficiency (LAL-D), also known as Wolman disease (WD) and cholesteryl ester storage disease (CESD). The intent of the drug policy is to ensure appropriate selection of patients for therapy based on product labeling, clinical guidelines, and clinical studies. Molina Healthcare reserves the right to update this Policy and revise coverage criteria to include or omit any off-label condition(s) as necessary based on medical literature and clinical studies that may become available. Kanuma (sebelipase alfa), an enzyme replacement therapy, is the first treatment approved by the Food and Drug Administration (FDA) that addresses the underlying cause of Lysosomal Acid Lipase Deficiency (LAL-D), a rare, serious, life-threatening lysosomal storage disease. Kanuma was granted orphan drug designation since it treatment of a rare disease affecting fewer than 200,000 patients in the United States. Sebelipase alfa is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme. Sebelipase alfa binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. Sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol, and free fatty acids. In patients with LAL deficiency, replacement with sebelipase alfa, a recombinant form of LAL, results in improvement in disease-related hepatic and lipid parameters.a Lysosomal Acid Lipase Deficiency (LAL-D) is an autosomal recessive lysosomal storage disorder caused by a genetic defect that leads to a marked decrease or loss in the activity of the LAL enzyme. 4,5,6 The deficiency leads to the accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and walls of blood vessels. The accumulation of lipids leads to increased liver fat content and progression of liver disease, which includes fibrosis and cirrhosis. LAL-D is associated with significant morbidity including hypercholesterolemia, cardiovascular disease, and liver damage. It may lead to liver failure and, in the most severe form, death. Lipid Page 1 of 16 accumulation in the intestinal wall leads to malabsorption and growth failure. Sebelipase alfa binds to cell surface receptors via glycans and is then internalized into lysosomes. LAL-D is caused by mutations affecting the LIPA gene—resulting in a deficiency of LAL enzyme activity in the lysosomes. Manifesting frequently in childhood, LAL-D was historically referred to as 2 separate disorders.1 The disease was previously known as Wolman’s disease in infants, and as cholesteryl ester storage disease in children and adults. However, it is now known that these conditions are both manifestations of the same disease13 and both presentations have come to be known as LAL-D. Wolman disease (WD) is an early onset form of LAL-D that is seen in infants and cholesteryl ester storage disease (CESD) another form of LAL-D with a later onset, seen in early childhood or later in life. WD: Wolman disease often presents during infancy (around 2 to 4 months of age) and is a rapidly progressive disease. Patients with Wolman disease rarely survive beyond the first year of life. A complete deficiency of the enzyme (estimated prevalence 1:500,000 live births) causes malabsorption, growth failure, hepatomegaly, adrenal cortical insufficiency, and death within the first year of life.9,10 CESD: CESD is a milder, later-onset form of LAL deficiency and presents in early childhood or later. Life expectancy of patients with CESD depends on the severity of the disease and associated complications. Partial LAL deficiency (estimated prevalence 1:40,000), which can present later in childhood or in adulthood, is associated with gastrointestinal symptoms, hepatosplenomegaly, elevated transaminase levels, and dyslipidemia, often progressing to hepatic fibrosis and cirrhosis and a need for liver transplantation. 9,10 Sebelipase alfa is currently the only treatment option that addresses the underlying pathophysiology of the disease. Previous treatments focused on management of symptoms caused by the disease and included supportive options such as dietary modifications, use of lipid-lowering agents (e.g. HMG-CoA reductase inhibitors, cholestyramine) such as statins alone or in combination with other modalities and medications (e.g., ezetimibe)6,13 liver transplantation,13 and hematopoietic stem cell transplantation (HSCT).13 However, no well-controlled studies have proven that any of these treatments are safe or effective in patients with LAL-D13,14 and do not address the underlying cause of disease. At present, there is limited information in the medical literature on the long-term outcomes of liver transplantation in patients with LAL-D. Liver transplantation itself also carries inherent significant risks, and requires concomitant immunosuppression. Furthermore, cells of hematopoietic lineage which will repopulate the transplanted liver will remain enzyme deficient in transplanted patients; hence, other disease complications may persist even if transplants are successful. Sebelipase alfa is administered intravenously as a 2-hour infusion every other week, or weekly for patients with rapidly progressive LAL-D presenting within the first 6 months of life. Sebelipase alfa appears to be a relatively safe and effective treatment for LAL deficiency. Treatment options for LAL­ D are limited, and the availability of this agent will be helpful in the management of this rare genetic disease. The evaluated studies suggest that sebelipase alfa therapy is associated with decreases in markers of the severity of LAL­ D, but findings have only been reported to 52 weeks. Although the number of patients exposed to sebelipase alfa in clinical trials was relatively low, the safety profile and efficacy analysis appear to be positive. Neutralizing antibodies to sebelipase alfa have developed and did not appear to compromise safety and efficacy; however findings over a longer duration of exposure are of interest. Therefore, a concern with this agent is the development of antidrug antibodies in some patients and the longer-term effect regarding the compromise of safety and efficacy. The effect of Kanuma on long‐term liver disease progression, potential reversal or stabilization of liver fibrosis, cardiovascular morbidity, and mortality has not been established. CLASSIFICATION: Recombinant Enzyme Replacement Agents Page 2 of 16 FDA INDICATIONS Lysosomal Acid Lipase Deficiency: Treatment of patients with lysosomal acid lipase deficiency (LAL-D).a Available as: 20 mg per 10 mL (2 mg/mL) solution in single-use vials for intravenous infusion FDA Approved: December 8, 2015 Sebelipase alfa was granted priority review by the FDA and received breakthrough therapy designation on December 8, 2015 as the first enzyme replacement therapy (ERT) for the treatment of patients of all ages with a diagnosis of LAL-D. Kanuma was also granted breakthrough therapy designation as it is the first and only treatment available for Wolman disease, the very severe infant form of the disease. Black Box Warnings: None at the time of this writing REMS: No REMS is required for sebelipase alfa at the time of this writing RECOMMENDATIONS/COVERAGE CRITERIA Kanuma (sebelipase alfa) may be authorized for members who meet ALL of the following criteria [ALL] 1. Prescriber specialty [ONE] Prescribed by, or in consultation with, a board-certified endocrinologist, clinical geneticist or specialist experienced in the treatment of inborn errors of metabolism. Submit consultation notes if applicable. NOTE: Consultation notes must be submitted for
Load more

Recommended publications
  • Lysosomal Acid Lipase Deficiency Lipid Insights December 9, 2013
    Lysosomal Acid Lipase Deficiency Lipid Insights December 9, 2013 Daniel J. Rader, MD LAL Deficiency . History . Pathophysiology and genetic epidemiology . Liver disease . Dyslipidemia and atherosclerosis . Diagnostic considerations . Therapeutic considerations . Summary Biology of Lysosomal Acid Lipase LDL particle lysosome Free cholesterol and free fatty acids nucleus Hepatocyte Lysosomal Acid Lipase (LAL) Deficiency: A single disease, with marked clinical heterogeneity LAL Deficiency is sometimes called: . Wolman disease (infantile presentation with growth failure) . Cholesteryl Ester Storage Disease or CESD (LAL deficiency presentation in children and adults) . Acid Cholesteryl Ester Hydrolase Deficiency, Type 2 . Acid Lipase Disease . Cholesteryl Ester Hydrolase Deficiency Storage Disease . LIPA Deficiency LAL Deficiency . History . Pathophysiology and genetic epidemiology . Liver disease . Dyslipidemia and atherosclerosis . Diagnostic considerations . Therapeutic considerations . Summary A brief history: The first phenotypic descriptions . Abramov, Shorr, and Wolman, 1956: “Generalized xanthomatosis with calcified adrenals” (“Wolman” disease) . Fredrickson, 1963: “Cholesterol ester storage disease” – “…likely a specific hepatic defect in cholesterol ester metabolism.” . Patrick and Lake : “Deficiency of an acid lipase in Wolman’s disease”, Nature, 1969 . Burke and Schubert : “Deficient activity of hepatic acid lipase in cholesterol ester storage disease”, Science, 1972 . Cortner et al: “Genetic variation of lysosomal acid lipase”, Pediatric Research, 1976 . Goldstein, et al: “Role of lysosomal acid lipase in the metabolism of plasma Low density lipoprotein,” JBC, 1975 . Anderson, et al: Cloning of the lysosomal acid lipase cDNA, JBC, 1991 . Anderson, et al: Mutations at the lysosomal acid cholesterol esterase gene locus in Wolman disease. Proc Natl Acad Sci USA, 1994 . Klima H, et al: “A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease.” J Clin Invest, 1993.
    [Show full text]
  • Pharmacy Medical Necessity Guidelines: Kanuma™ (Sebelipase Alfa) Effective: April 13, 2021
    Pharmacy Medical Necessity Guidelines: Kanuma™ (sebelipase alfa) Effective: April 13, 2021 Prior Authorization Required √ Type of Review – Care Management Not Covered Type of Review – Clinical Review √ PRECERT Pharmacy (RX) or Medical (MED) Benefit MED Department to Review /MM These pharmacy medical necessity guidelines apply to the following: Fax Numbers: Commercial Products Tufts Health Plan Commercial products – large group plans Commercial Products: Tufts Health Plan Commercial products – small group and individual plans PRECERT: 617.972.9409 Tufts Health Freedom Plan products – large group plans Tufts Health Freedom Plan products – small group plans Tufts Health Public • CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization Plans Products: MM: 888.415.9055 Tufts Health Public Plans Products Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans Tufts Health RITogether – A Rhode Island Medicaid Plan Note: This guideline does not apply to Medicare Members (includes dual eligible Members). OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS Kanuma (sebelipase) is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. Lysosomal Acid Lipase deficiency is an autosomal recessive lysosomal storage disorder characterized by a genetic defect (mutation in the LIPA gene) resulting in a marked decrease or loss in activity of the LAL enzyme. The primary site of action of the LAL enzyme is the lysoso me, where the enzyme normally causes the breakdown of lipid particles. Deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and the walls of blood vessels.
    [Show full text]
  • ICD-9-CM C&M March 2011 Diagnosis Agenda
    ICD-10 Coordination and Maintenance Committee Meeting September 22-23, 2015 Diagnosis Agenda Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee Diagnosis Topics: Contents Abscess of Anal and Rectal Regions .............................................................................. 12 Cheryl Bullock Garth H. Utter, MD MSc Patient Assessment and Outcome Committee Outcome of the American Association for the Surgery of Trauma Acquired Hydrocephalus ................................................................................................ 15 Donna Pickett Amblyopia Suspect ........................................................................................................ 16 Shannon McConnell Lamptey Michael X Repka, M.D., MBA Medical Director of Government Affairs American Academy of Ophthalmology Professor of Ophthalmology and Pediatrics Johns Hopkins University School of Medicine Amyotrophic Lateral Sclerosis (ALS) .......................................................................... 17\ Donna Pickett Asthma Control Status: Controlled and Uncontrolled .................................................... 18 Cheryl Bullock Elizabeth Matsu, MD, MHS American Academy of Allergy Asthma and Immunology (AAAAI) Professor of Pediatrics, Epidemiology, and Environmental Health Sciences at Johns Hopkins University Atrial Fibrillation ........................................................................................................... 20 David Berglund, MD Chronic hepatitis
    [Show full text]
  • WO 2015/051214 Al 9 April 2015 (09.04.2015) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/051214 Al 9 April 2015 (09.04.2015) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/705 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 14/058967 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 3 October 2014 (03. 10.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/886,137 3 October 201 3 (03. 10.2013) US (84) Designated States (unless otherwise indicated, for every 61/903,485 13 November 2013 (13. 11.2013) US kind of regional protection available): ARIPO (BW, GH, 61/952,906 14 March 2014 (14.03.2014) us GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/052,139 18 September 2014 (18.09.2014) us TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: MODERNA THERAPEUTICS, INC.
    [Show full text]
  • WO 2016/164762 Al 13 October 2016 (13.10.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/164762 Al 13 October 2016 (13.10.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/705 (2006.01) C12N 15/11 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/09 (2006.01) C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/026703 HN, HR, HU, ID, IL, ΓΝ , IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 8 April 2016 (08.04.2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/144,895 8 April 2015 (08.04.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: MODERNA THERAPEUTICS, INC.
    [Show full text]
  • Health and Medicine Volume 4
    The Eyes iii THE FACTS ON FILE ENCYCLOPEDIA OF HEALTH AND MEDICINE IN FOUR VOLUMES: VOLUME 4 An Amaranth Book iv The Eyes To your health! The information presented in The Facts On File Encyclopedia of Health and Medicine is provided for research purposes only and is not intended to replace consultation with or diagnosis and treatment by medical doctors or other qualified experts. Readers who may be experiencing a condition or disease described herein should seek medical attention and not rely on the information found here as medical advice. The Facts On File Encyclopedia of Health and Medicine in Four Volumes: Volume 4 Copyright © 2007 by Amaranth Illuminare All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval systems, without permission in writing from the publisher. For information contact: Facts On File, Inc. An imprint of Infobase Publishing 132 West 31st Street New York NY 10001 Produced by Amaranth Illuminare PO Box 573 Port Townsend WA 98368 Library of Congress Cataloging-in-Publication Data The Facts on File encyclopedia of health and medicine / Amaranth Illuminare and Deborah S. Romaine. p. ; cm. “An Amaranth book.” Includes index. ISBN 0-8160-6063-0 (hc : alk. paper) 1. Medicine—Encyclopedias. 2. Health—Encyclopedias. [DNLM: 1. Medicine—Encyclopedias—English. 2. Physiological Processes—Encyclopedias—English. WB 13 R842f 2006] I. Title: Encyclopedia of health and medicine. II. Romaine, Deborah S., 1956- III. Facts on File, Inc. IV. Title. R125.R68 2006 610.3—dc22 2005027679 Facts On File books are available at special discounts when purchased in bulk quantities for businesses, associations, institutions, or sales promotions.
    [Show full text]
  • ICD-9-CM C&M March 2011 Diagnosis Agenda
    ICD-10 Coordination and Maintenance Committee Meeting September 22-23, 2015 Diagnosis Agenda Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee Diagnosis Topics: Contents Abscess of Anal and Rectal Regions ............................................................................... 12 Cheryl Bullock Garth H. Utter, MD MSc Patient Assessment and Outcome Committee Outcome of the American Association for the Surgery of Trauma Acquired Hydrocephalus ................................................................................................. 15 Donna Pickett Amblyopia Suspect .......................................................................................................... 16 Shannon McConnell Lamptey Michael X Repka, M.D., MBA Medical Director of Government Affairs American Academy of Ophthalmology Professor of Ophthalmology and Pediatrics Johns Hopkins University School of Medicine Amyotrophic Lateral Sclerosis (ALS) ............................................................................ 17\ Donna Pickett Asthma Control Status: Controlled and Uncontrolled ..................................................... 18 Cheryl Bullock Elizabeth Matsu, MD, MHS American Academy of Allergy Asthma and Immunology (AAAAI) Professor of Pediatrics, Epidemiology, and Environmental Health Sciences at Johns Hopkins University Atrial Fibrillation ............................................................................................................. 20 David Berglund, MD Chronic
    [Show full text]
  • Universidade Federal De Santa Catarina Centro De Ciências Da Saúde Programa De Pós-Graduação Em Ciências Médicas
    UNIVERSIDADE FEDERAL DE SANTA CATARINA CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS MÉDICAS CAMILA DA ROSA WITECK Características clínicas e laboratoriais de pacientes pediátricos com deficiência de lipase ácida: Scoping Review. Florianópolis 2021 CAMILA DA ROSA WITECK Características clínicas e laboratoriais de pacientes pediátricos com deficiência de lipase ácida: Scoping Review. Dissertação submetida ao Programa de Ciências Médicas da Universidade Federal de Santa Catarina para a obtenção do título de mestre em ciências médicas Orientadora: Profa. Dra. Maria Marlene de Souza Pires Florianópolis 2021 CAMILA DA ROSA WITECK Características clinicas e laboratoriais de pacientes pediátricos com deficiência de lipase ácida : Scoping Review. O presente trabalho em nível de mestrado foi avaliado e aprovado por banca examinadora composta pelos seguintes membros: Prof.(a)Maria Marlene de Souza Pires, Dr.(a) Universidade Federal de Santa Catarina Prof.(a) Suely Grosseman , Dr.(a) Universidade Federal de Santa Catarina Prof.(a) Priscyla Walesca Targino de Azevedo Simões, Dr.(a) Universidade Federal do ABC Certificamos que esta é a versão original e final do trabalho de conclusão que foi julgado adequado para obtenção do título de mestre em Ciências Médicas. ____________________________ Profa. Katia Lin, Dra. Coordenação do Programa de Pós-Graduação ____________________________ Profa. Maria Marlene de Souza Pires, Dra. Orientadora Florianópolis 2021 A toda minha família, a base sólida do meu crescimento pessoal e profissional. AGRADECIMENTOS À Dra. Maria Marlene de Souza Pires, orientadora deste trabalho, pela dedicação e apoio. Sua importância em minha vida acadêmica e pessoal iniciou-se na graduação de Medicina pelas brilhantes observações, competência no âmbito profissional e acadêmico.
    [Show full text]
  • ICD-10-CM C&M September Diagnosis Agenda
    ICD-10 Coordination and Maintenance Committee Meeting September 22-23, 2015 Diagnosis Agenda Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee Diagnosis Topics: Contents Abscess of Anal and Rectal Regions ............................................................................... 12 Cheryl Bullock Garth H. Utter, MD MSc Patient Assessment and Outcome Committee Outcome of the American Association for the Surgery of Trauma Acquired Hydrocephalus ................................................................................................. 15 Donna Pickett Amblyopia Suspect .......................................................................................................... 16 Shannon McConnell Lamptey Michael X Repka, M.D., MBA Medical Director of Government Affairs American Academy of Ophthalmology Professor of Ophthalmology and Pediatrics Johns Hopkins University School of Medicine Amyotrophic Lateral Sclerosis (ALS) ............................................................................. 17 Donna Pickett Asthma Control Status: Controlled and Uncontrolled ..................................................... 18 Cheryl Bullock Elizabeth Matsu, MD, MHS American Academy of Allergy Asthma and Immunology (AAAAI) Professor of Pediatrics, Epidemiology, and Environmental Health Sciences at Johns Hopkins University Atrial Fibrillation ............................................................................................................. 20 David Berglund, MD Chronic
    [Show full text]
  • Vol. 19, No. 2, 2018 Make.Pmd
    J MEDICINE 2018; 19: 130-132 Cholesteryl Ester Storage Disease – A Rare Presentation MADHABI KARMAKER,1 SARMIN AKTER,2 AHMEDUL KABIR,3 KHAN ABUL KALAM AZAD,4 ABID HOSSAIN MOLLAH5 Abstract: Cholesteryl Ester Storage Disease (CESD) is a rare genetic disease characterized by accumulation of cholesteryl esters and triglycerides in many tissues due to deficiency of Lysosomal Acid Lipase (LAL/ LIPA) enzyme, which is essential for hydrolysis of triglycerides and cholesterol esters in lysosomes.1 The diagnosis is indicated by abnormal lipid profile, deposition of cholesterol crystals in internal organs and reduced acid lipase activity in leukocytes. Here we report a 16 year-old girl who presented with repeated episodes of hepatic encephalopathy with onset of first symptom at 9 years of age with history of consanguinity of marriage between parents. On examination, we found hepatosplenomegaly. Laboratory examination showed abnormal lipid profile and reduced activity of acid lipase enzyme in leukocytes. After exclusion of other possible pathological conditions and on the basis of lab criteria, we diagnose the case as Cholesteryl Ester Storage Disease (CESD). KKKeeeywords: Cholesteryl Ester Storage Disease (CESD), cholesteryl esters, triglycerides, Lysosomal Acid Lipase. DOI: http://dx.doi.org/10.3329/jom.v19i2.37235 Introduction: symptoms and may go undiagnosed until adulthood. CESD CESD is inherited as an autosomal recessive condition 1 So is characterized by alterations of blood lipoprotein profile; parents who are close relatives (consanguineous) have a patients present with hypercholesterolemia, higher chance to have children with a recessive genetic hypertriglyceridaemia, HDL deficiency with abnormal lipid disorder. CESD affects males and females in equal numbers.2 deposition in many organs.
    [Show full text]
  • Kasenra Sebelipase Alfa MCP289
    Subject: Kanuma (sebelipase alfa) Original Effective Date: 11/21/2016 Policy Number: MCP-289 Revision Date(s): Review Date(s): DISCLAIMER This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP document and provide the directive for all Medicare members. SUMMARY OF EVIDENCE/POSITION This policy addresses the coverage of Kanuma (sebelipase alfa), a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme administered intravenously for the treatment of the rare disease lysosomal acid lipase deficiency (LAL-D), also known as Wolman disease (WD) and cholesteryl ester storage disease (CESD).
    [Show full text]